Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($66.38).

• How does this merchantability comparison to Savage's humanities trading activity?
  The 5,731-share merchantability aligns with Savage's 13 anterior open-market dispositions, wherever the mean size has been astir 5,091 shares, indicating the transaction is wrong his established signifier of commercialized sizes.

• What information of Savage's holdings does this transaction represent?
  This merchantability accounted for 6.73% of his nonstop holdings astatine the time, reducing his presumption from 85,211 shares to 79,480 shares, and leaving him with nary indirect oregon derivative vulnerability post-transaction.

• Was this merchantability conducted nether a pre-arranged plan?
  Yes, the filing specifies that the transactions were effected pursuant to a Rule 10b5-1 trading program adopted connected October 2, 2025.

• What is the existent worth of Savage's remaining position, and however does it comparison to the company's performance?
  As of April 13, 2026, his nonstop holdings were valued astatine astir $5.44 million, portion Disc Medicine shares person appreciated 70.0% implicit the anterior 12 months, underscoring some the standard of his retained involvement and the company's caller equity performance.

Note: 1-year show is calculated utilizing April 13, 2026 arsenic the notation date.

• Disc Medicine develops and advances a portfolio of clinical-stage therapeutic candidates targeting hematologic diseases, focusing connected reddish humor compartment biology, heme biosynthesis, and robust homeostasis.

• The institution operates a research-driven model, generating worth done the find and objective improvement of caller cause candidates for superior humor disorders.

• Primary customers see healthcare providers and patients affected by hematologic diseases, with a people marketplace spanning uncommon and superior humor disorders globally.

Disc Medicine is simply a clinical-stage biotechnology institution specializing successful the improvement of innovative therapies for hematologic diseases. The institution leverages expertise successful reddish humor compartment biology to code unmet aesculapian needs done a robust pipeline of caller cause candidates. Its strategical absorption connected cardinal biologic pathways provides a differentiated attack wrong the biotechnology sector.